印度HIV合并内脏利什曼病患者中AmBisome单药与AmBisome-米替福新联合治疗的随机开放标签平行组3期试验
在印度巴特那单家医院开展的随机开放标签平行组3期试验中,150例HIV合并内脏利什曼病患者随机接受AmBisome单药(总40 mg/kg,24天内8次等剂量)或AmBisome(总30 mg/kg,6次等剂量)联合米替福新(总1.4 g,14天内每日两次50 mg)。第210天无复发生存率单药组85%(64/75;95%CI 77-100%),联合组96%(72/75;90-100%);排除合并结核者后分别为90%(55/61;82-100%)和97%(59/61;91-100%)。严重不良事件少见且两组相似。作者认为联合治疗安全、耐受良好、有效,并将当前推荐疗程减半。
要点
- HIV合并内脏利什曼病患者中,AmBisome联合米替福新第210天无复发生存率96%,单药组85%。
- 排除合并结核者后,联合组无复发生存率97%,单药组90%。
- 严重不良事件少见且两组相似,联合治疗将当前推荐疗程减半。
核心结论
- 联合治疗(AmBisome联合米替福新)看似安全、耐受良好且有效,并将当前推荐的治疗疗程减半。
研究设计与样本
- 随机、开放标签、平行组3期试验,在印度巴特那单家医院开展。
- 150例年龄≥18岁、血清学确诊HIV且寄生虫学确诊内脏利什曼病的患者随机分配至2个治疗组之一。
- 单药组:静脉脂质体两性霉素B(AmBisome;Gilead Pharmaceuticals)总40 mg/kg,24天内分8次等剂量给药。
- 联合组:静脉AmBisome总30 mg/kg,分6次等剂量给药,同时口服米替福新总1.4 g,14天内每日两次50 mg。
- 主要结局为第210天意向性治疗无复发生存,定义为无内脏利什曼病体征和症状,或如有症状则寄生虫学检查阴性。
主要发现
- 243例患者接受资格评估,150例于2017年1月2日至2018年4月5日期间入组,无失访。
- 第210天无复发生存率:单药组85%(64/75;95%CI 77-100%),联合组96%(72/75;90-100%)。
- 19%(28/150)合并结核感染,两组均等分配。
- 排除合并结核者后,第210天无复发生存率:单药组90%(55/61;82-100%),联合组97%(59/61;91-100%)。
- 严重不良事件少见且两组相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Visceral leishmaniasis (VL) in patients with human immunodeficiency virus (HIV) presents an increasingly important patient cohort in areas where both infections are endemic. Evidence for treatment is sparce, with no high-quality studies from the Indian subcontinent. METHODS: This is a randomized, open-label, parallel-arm, phase 3 trial conducted within a single hospital in Patna, India. One hundred and fifty patients aged ≥18 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30 mg/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1.4 g oral miltefosine administered through 2 daily doses of 50 mg over 14 days. The primary outcome was intention-to-treat relapse-free survival at day 210, defined as absence of signs and symptoms of VL or, if symptomatic, negative parasitological investigations. RESULTS: Among 243 patients assessed for eligibility, 150 were recruited between 2 January 2017 and 5 April 2018, with no loss to follow-up. Relapse-free survival at day 210 was 85% (64/75; 95% CI, 77-100%) in the monotherapy arm, and 96%, (72/75; 90-100%) in the combination arm. Nineteen percent (28/150) were infected with concurrent tuberculosis, divided equally between arms. Excluding those with concurrent tuberculosis, relapse-free survival at day 210 was 90% (55/61; 82-100%) in the monotherapy and 97% (59/61; 91-100%) in the combination therapy arm. Serious adverse events were uncommon and similar in each arm. CONCLUSIONS: Combination therapy appears to be safe, well tolerated, and effective, and halves treatment duration of current recommendations. CLINICAL TRIALS REGISTRATION: Clinical Trial Registry India (CTRI/2015/05/005807; the protocol is available online at https://osf.io/avz7r).
引用
- Burza S, Mahajan R, Kazmi S, et al. AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. Clin Infect Dis. 2022. PMID: 35147680. doi:10.1093/cid/ciac127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。